Loading...
Loading...
Jefferies reiterated its Buy rating on DexCom
DXCM, but raised price target on its shares from $17 to $19.50 in a research report published today.
In the report, Jefferies states, "DexCom reported 1Q revenues of $14.2mn which was slightly shy of street forecasts, but earnings were in line with estimates at ($0.19). New patient adds remained strong for the quarter and the softness appears largely driven by lighter sensor utilization as patients work through their yearly deductibles. The best in class technology and strong revenue growth keep us at a Buy."
In today's trading, DexCom lost 0.06% to stand at $16.49.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Posted In: Analyst ColorEarningsPrice TargetAnalyst RatingsdexcomHealth CareHealth Care EquipmentJefferies
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in